Enhancing communication about cancer management and cancer care delivery for older adults with dementia and their care partners.

TPS12166 Background: Dementia affects 7–10% of older adults with cancer and is associated with worse cancer outcomes. Many patients (pts) have reduced decisional capacity, leading care partners (CPs) to play a major role in cancer management decision-making, which can increase CP burden and negatively affect their well-being. Cancer communication in this population is complex, requiring clinicians to balance pt preferences, CP input, and dementia-related considerations. Despite this, no standard approach exists to support triadic communication in this setting. COACH-Cog is a triadic communication intervention that promotes shared decision-making by integrating CP involvement while centering pt values in cancer care. Methods: Eligibility: Pts are age ≥65 with a diagnosis of dementia and cancer (any type or stage), have an identified CP, and receive oncology care from a participating clinician. CPs are age ≥18 and identified by the pt. Oncology clinicians (physicians or advanced practice providers) must practice at the Wilmot Cancer Institute. Study Design: This is a pilot cluster-randomized trial (clinician-level randomization). The COACH-Cog intervention includes: 1) a brief clinician training video on dementia and its relevance to cancer care; 2) distribution of pt geriatric assessment results with care recommendations to clinicians, pts, and CPs; and (3) CP communication coaching to elicit dementia-related concerns and develop questions for the next oncology visit. Baseline measures include pt geriatric assessment and dementia severity, CP well-being (burden, quality of life, depression, anxiety), and pt/CP communication and decision-making preferences. Pts and CPs receive either COACH-Cog or usual care based on clinician randomization. The subsequent clinical encounter is audio-recorded. Outcome Measures: The primary outcome is CP autonomy support, which evaluates how supported CPs feel in the decision-making process. Secondary outcomes include healthcare communication and CP well-being. Tertiary outcomes assess goal-concordant care and decisional regret. Exploratory outcomes evaluate communication impact by integrating qualitative clinical encounter data with quantitative measures. Current enrollment includes 36 clinicians and 36 pt/CP dyads (target 40 clinicians, 130 dyads). Accrual initiated April 2025. Data collection will conclude May 2027 (NCT06313853; NIA R01 AG077053). Novel/Innovative aspects: (1) This is the first study to prospectively enroll patients with dementia in an oncology intervention trial; (2) We are evaluation of a novel triadic communication intervention targeting clinicians, pts, and CPs; and (3) We have incorporated standard procedures for assessing consent capacity and engaging Legally Authorized Representatives for pts lacking capacity given enrollment of pts with dementia. Clinical trial information: NCT06313853 .

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-28
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.tps12166
Primary Topic
Cancer-related cognitive impairment studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Enhancing communication about cancer management and cancer care delivery for older adults with dementia and their care partners.

M. Wilgucki, Nancy Dukelow, Emilyn Nguyen, Supriya G. Mohile et al.
Journal of Clinical Oncology
Cancer-related cognitive impairment studies
article

Enhancing communication about cancer management and cancer care delivery for older adults with dementia and their care partners.

M. Wilgucki, Nancy Dukelow, Emilyn Nguyen, Supriya G. Mohile, Michelle C. Janelsins, S. Hryniv, Anna Job, Kathi Heffner, Jessica Mortimer, Allison Magnuson, Oscar Franco-Rocha, Davida Rogers, Jessica Bauer
article en

Abstract

TPS12166 Background: Dementia affects 7–10% of older adults with cancer and is associated with worse cancer outcomes. Many patients (pts) have reduced decisional capacity, leading care partners (CPs) to play a major role in cancer management decision-making, which can increase CP burden and negatively affect their well-being. Cancer communication in this population is complex, requiring clinicians to balance pt preferences, CP input, and dementia-related considerations. Despite this, no standard approach exists to support triadic communication in this setting. COACH-Cog is a triadic communication intervention that promotes shared decision-making by integrating CP involvement while centering pt values in cancer care. Methods: Eligibility: Pts are age ≥65 with a diagnosis of dementia and cancer (any type or stage), have an identified CP, and receive oncology care from a participating clinician. CPs are age ≥18 and identified by the pt. Oncology clinicians (physicians or advanced practice providers) must practice at the Wilmot Cancer Institute. Study Design: This is a pilot cluster-randomized trial (clinician-level randomization). The COACH-Cog intervention includes: 1) a brief clinician training video on dementia and its relevance to cancer care; 2) distribution of pt geriatric assessment results with care recommendations to clinicians, pts, and CPs; and (3) CP communication coaching to elicit dementia-related concerns and develop questions for the next oncology visit. Baseline measures include pt geriatric assessment and dementia severity, CP well-being (burden, quality of life, depression, anxiety), and pt/CP communication and decision-making preferences. Pts and CPs receive either COACH-Cog or usual care based on clinician randomization. The subsequent clinical encounter is audio-recorded. Outcome Measures: The primary outcome is CP autonomy support, which evaluates how supported CPs feel in the decision-making process. Secondary outcomes include healthcare communication and CP well-being. Tertiary outcomes assess goal-concordant care and decisional regret. Exploratory outcomes evaluate communication impact by integrating qualitative clinical encounter data with quantitative measures. Current enrollment includes 36 clinicians and 36 pt/CP dyads (target 40 clinicians, 130 dyads). Accrual initiated April 2025. Data collection will conclude May 2027 (NCT06313853; NIA R01 AG077053). Novel/Innovative aspects: (1) This is the first study to prospectively enroll patients with dementia in an oncology intervention trial; (2) We are evaluation of a novel triadic communication intervention targeting clinicians, pts, and CPs; and (3) We have incorporated standard procedures for assessing consent capacity and engaging Legally Authorized Representatives for pts lacking capacity given enrollment of pts with dementia. Clinical trial information: NCT06313853 .

Journal of Clinical OncologyVol. 44(16_suppl)
University of Rochester Medical Center (US), University of Rochester (US)
Peace, Justice and strong institutions
Openalex Percentile: Top 6%
Cancer-related cognitive impairment studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.